Sanofi
Follow13F filer, CIK 1121404, Paris, France
Sanofi reported $629,867,590 across 16 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-05. Its ten largest share positions make up 92.09% of the portfolio.
Accepted , ingested 13F-HR 0001193125-26-448717
- Period
- 2026-09-30
- Reported value
- $630M
- Holdings
- 16
- Top 10 weight
- 92.09%
- New
- 6
- Sold out
- 0
Largest buys vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| KRSAnew | +1,994,011 | $63.8M |
| ETRAnew | +2,461,948 | $27.7M |
| ATTOnew | +1,082,855 | $18.6M |
| LTGOnew | +672,778 | $11.2M |
| SCTXnew | +500,000 | $9.2M |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Largest sells vs the previous quarter
| Security | Shares change | Approx. value |
|---|---|---|
| ODTXreduced | -1,718 | -$38.2K |
Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.
Holdings, Q3 2026
Share positions as resolved from 13F-HR 0001193125-26-448717, largest first. % of portfolio is the value over $629,867,590, the sum of the share positions whose value is usable for ratios (method).
| Security | History | Shares | Value | % of portfolio | Change | Latest event | Timeline |
|---|---|---|---|---|---|---|---|
| MGTXMEIRAGTX HLDGS PLC | 12,197,737 | $134M | 21.3% | 0 | Timeline | ||
| INBXINHIBRX BIOSCIENCES INC | 1,157,926 | $116M | 18.4% | 0 | Timeline | ||
| NVAXNOVAVAX INC | 6,880,481 | $74.4M | 11.81% | 0 | Timeline | ||
| KRSAKORSANA BIOSCIENCES INC | 1,994,011 | $63.8M | 10.13% | new | Timeline | ||
| ODTXODYSSEY THERAPEUTICS INC | 1,990,200 | $44.2M | 7.02% | -1,718 | Timeline | ||
| ANABANAPTYSBIO INC | 821,917 | $41.3M | 6.56% | 0 | Timeline | ||
| AGMBAGOMAB THERAPEUTICS NV | 2,783,096 | $30.9M | 4.9% | 0 | Timeline | ||
| TRAXFIRST TRACKS BIOTHERAPEUTICS | 821,917 | $29.1M | 4.62% | 0 | Timeline | ||
| ETRAELECTRA THERAPEUTICS INC | 2,461,948 | $27.7M | 4.4% | new | Timeline | ||
| ATTOATTOVIA THERAPEUTICS INC | 1,082,855 | $18.6M | 2.95% | new | Timeline | ||
| LTGOLATIGO BIOTHERAPEUTICS INC | 672,778 | $11.2M | 1.78% | new | Timeline | ||
| IMRXIMMUNEERING CORP | 2,708,559 | $11.1M | 1.76% | 0 | Timeline | ||
| MPLTMAPLIGHT THERAPEUTICS INC | 912,041 | $9.29M | 1.48% | 0 | Timeline | ||
| SCTXSCRIBE THERAPEUTICS INC | 500,000 | $9.2M | 1.46% | new | Timeline | ||
| SABSSAB BIOTHERAPEUTICS INC | 2,198,500 | $6.97M | 1.11% | new | Timeline | ||
| QTTBQ32 BIO INC | 244,083 | $2.02M | 0.32% | 0 | Timeline |
How Q3 2026 was built
Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).
| Filing | Role | Amendment | Filed | Accepted | Ingested |
|---|---|---|---|---|---|
| 13F-HR 0001193125-26-448717 | base | 2026-11-05 |
Filings
Every filing of this filer: 13F reports and notices, the 13D and 13G it filed or is a reporting person of, and Forms 3, 4 and 5 it reported as an owner.
| Filing | Subject | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0001193125-26-448717 | Quarter ended 2026-09-30 | 2026-11-05 | ||
| 13F-HR 0001193125-26-318812 | Quarter ended 2026-06-30 | 2026-07-28 | acceptance time not in the bulk data set | |
| 13F-HR 0001193125-26-210525 | Quarter ended 2026-03-31 | 2026-05-07 | acceptance time not in the bulk data set | |
| 13F-HR 0001193125-26-045633 | Quarter ended 2025-12-31 | 2026-02-11 | acceptance time not in the bulk data set | |
| 13F-HR 0001193125-25-263831 | Quarter ended 2025-09-30 | 2025-11-04 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-25-006717 | Quarter ended 2025-06-30 | 2025-07-29 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-25-004066 | Quarter ended 2025-03-31 | 2025-05-06 | acceptance time not in the bulk data set | |
| 13F-HR 0000950123-25-002465 | Quarter ended 2024-12-31 | 2025-02-14 | acceptance time not in the bulk data set |